BRPI0513855A - células "homing" tumorais engenheiradas para produzir ligante indutor de apoptose relacionada ao fator de necrose tumoral (trail) por transferência de gene mediada por adenovìrus - Google Patents

células "homing" tumorais engenheiradas para produzir ligante indutor de apoptose relacionada ao fator de necrose tumoral (trail) por transferência de gene mediada por adenovìrus

Info

Publication number
BRPI0513855A
BRPI0513855A BRPI0513855-8A BRPI0513855A BRPI0513855A BR PI0513855 A BRPI0513855 A BR PI0513855A BR PI0513855 A BRPI0513855 A BR PI0513855A BR PI0513855 A BRPI0513855 A BR PI0513855A
Authority
BR
Brazil
Prior art keywords
trail
necrosis factor
related apoptosis
tumor
adenovirus
Prior art date
Application number
BRPI0513855-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Alessandro M Gianni
Carmelo Carlo-Stella
Francesco Colotta
Original Assignee
Dompe Pha R Ma Spa Res & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Pha R Ma Spa Res & Mfg filed Critical Dompe Pha R Ma Spa Res & Mfg
Publication of BRPI0513855A publication Critical patent/BRPI0513855A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464438—Tumor necrosis factors [TNF], CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0513855-8A 2004-07-29 2005-07-21 células "homing" tumorais engenheiradas para produzir ligante indutor de apoptose relacionada ao fator de necrose tumoral (trail) por transferência de gene mediada por adenovìrus BRPI0513855A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017907A EP1621550A1 (fr) 2004-07-29 2004-07-29 Cellules ciblant des tumeurs, exprimant la protéine "tumor necrosis factor-related apoptosis inducing ligand" (TRAIL)
PCT/EP2005/007957 WO2006010558A1 (fr) 2004-07-29 2005-07-21 Cellules de localisation tumorale genetiquement modifiees pour la production de ligand inducteur d'apoptose relie au facteur de necrose tumorale (trail)

Publications (1)

Publication Number Publication Date
BRPI0513855A true BRPI0513855A (pt) 2008-05-20

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513855-8A BRPI0513855A (pt) 2004-07-29 2005-07-21 células "homing" tumorais engenheiradas para produzir ligante indutor de apoptose relacionada ao fator de necrose tumoral (trail) por transferência de gene mediada por adenovìrus

Country Status (25)

Country Link
US (1) US20070264231A1 (fr)
EP (2) EP1621550A1 (fr)
JP (1) JP5042826B2 (fr)
KR (1) KR20070047757A (fr)
CN (1) CN101076540B (fr)
AT (1) ATE455847T1 (fr)
AU (1) AU2005266543B2 (fr)
BR (1) BRPI0513855A (fr)
CA (1) CA2571426A1 (fr)
DE (1) DE602005019050D1 (fr)
DK (1) DK1771468T3 (fr)
ES (1) ES2340400T3 (fr)
HK (1) HK1110874A1 (fr)
HR (1) HRP20100227T1 (fr)
IL (1) IL180233A (fr)
MX (1) MX2007001152A (fr)
NO (1) NO20070956L (fr)
NZ (1) NZ552223A (fr)
PL (1) PL1771468T3 (fr)
PT (1) PT1771468E (fr)
RS (1) RS51381B (fr)
RU (1) RU2390558C2 (fr)
SI (1) SI1771468T1 (fr)
WO (1) WO2006010558A1 (fr)
ZA (1) ZA200701231B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070050911A (ko) * 2004-06-18 2007-05-16 제넨테크, 인크. Ａｐｏ２ｌ 수용체 작동제 및 ｎｋ 세포 활성화제의 사용방법
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
WO2008142862A1 (fr) * 2007-05-18 2008-11-27 National University Corporation Asahikawa Medical College Thérapie anticancéreuse par transplantation de cellules souches endothéliales vasculaires
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
EP2811023B1 (fr) * 2012-02-01 2018-10-24 Postech Academy-Industry Foundation Vecteur exprimant simultanément trail dodécamère et des gènes suicides hsv-tk, et agent thérapeutique anticancéreux à base de cellules souches l'utilisant
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
EP3209382B1 (fr) 2014-10-24 2020-11-25 Calidi Biotherapeutics, Inc. Technique d'immunotherapie combinee pour le traitement du cancer
ES2890859T3 (es) 2015-07-29 2022-01-24 Onk Therapeutics Ltd Células asesinas naturales modificadas y líneas de células asesinas naturales que tienen citotoxicidad aumentada
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2019232631A1 (fr) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions et méthodes d'enrichissement en cellules suppressives dérivées de cellules myéloïdes
US20220143089A1 (en) * 2019-03-21 2022-05-12 Onk Therapeutics Limited Modified immune effector cells with increased resistance to cell death
EP3712257A1 (fr) 2019-03-21 2020-09-23 ONK Therapeutics Limited Cellules tueuses naturelles modifiées présentant une résistance accrue à la mort cellulaire
WO2021209625A1 (fr) 2020-04-17 2021-10-21 Onk Therapeutics Limited Cellules tueuses naturelles à haute activité

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332435T3 (es) * 1997-06-04 2010-02-04 Oxford Biomedica (Uk) Limited Vector dirigido a tumores.
AU2001290720A1 (en) * 2000-09-11 2002-03-26 Musc Foundation For Research Development Method and composition for treating tumors by selective induction of apoptosis
WO2002066044A2 (fr) * 2000-10-24 2002-08-29 Immunex Corporation Procede de traitement de tumeurs utilisant une polytherapie
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Also Published As

Publication number Publication date
SI1771468T1 (sl) 2010-07-30
HK1110874A1 (en) 2008-07-25
EP1771468B1 (fr) 2010-01-20
WO2006010558A1 (fr) 2006-02-02
ES2340400T3 (es) 2010-06-02
JP5042826B2 (ja) 2012-10-03
NZ552223A (en) 2009-01-31
RS51381B (en) 2011-02-28
PL1771468T3 (pl) 2010-07-30
KR20070047757A (ko) 2007-05-07
AU2005266543A1 (en) 2006-02-02
CN101076540B (zh) 2012-10-24
RU2390558C2 (ru) 2010-05-27
EP1771468A1 (fr) 2007-04-11
NO20070956L (no) 2007-02-20
IL180233A (en) 2010-12-30
DE602005019050D1 (de) 2010-03-11
CA2571426A1 (fr) 2006-02-02
AU2005266543B2 (en) 2012-02-02
RU2007107369A (ru) 2008-09-10
DK1771468T3 (da) 2010-05-25
MX2007001152A (es) 2007-04-18
JP2008507961A (ja) 2008-03-21
PT1771468E (pt) 2010-04-20
HRP20100227T1 (hr) 2010-07-31
ZA200701231B (en) 2008-08-27
CN101076540A (zh) 2007-11-21
ATE455847T1 (de) 2010-02-15
IL180233A0 (en) 2007-07-04
US20070264231A1 (en) 2007-11-15
EP1621550A1 (fr) 2006-02-01
WO2006010558A8 (fr) 2006-08-24

Similar Documents

Publication Publication Date Title
BRPI0513855A (pt) células "homing" tumorais engenheiradas para produzir ligante indutor de apoptose relacionada ao fator de necrose tumoral (trail) por transferência de gene mediada por adenovìrus
Sarkar et al. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice
BRPI0418805B8 (pt) construção de recombinante de adenovírus oncolítico expressando especificamente um fator imunomodulatório gmcsf em células tumorais e seus usos
HK1109421A1 (en) Chimeric adenoviruses for use in cancer treatment
Jäger et al. The enigmatic roles of caspases in tumor development
SG170080A1 (en) Human monoclonal antibodies to o8e
WO2006089230A3 (fr) Anticorps monoclonaux humains diriges contre l'antigene d'enveloppe specifique de la prostate
WO2008005954A3 (fr) Modulateurs de protéine signal en tant qu'agents thérapeutiques
EP1623990A3 (fr) Compositions et procédures pour le traitement de tumeurs
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
WO2002078598A3 (fr) Peptides et anticorps destines a des proteines muc 1
Pedersen et al. The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer
Singh et al. Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells
WO2009097014A3 (fr) Modulateurs de kinase thérapeutiques
WO2006110240A3 (fr) Transfert de genes au moyen d'adenovirus presentant des proteines fibres modifiees
EP1898803A4 (fr) Aberrations moléculaires/génétiques détectées dans les marges chirurgicales d'un cancer du pancréas reséqué représentant une maladie néoplasique correspondant à l'évolution de la maladie
Duro de Oliveira et al. Higher incidence of lung adenocarcinomas induced by DMBA in connexin 43 heterozygous knockout mice
ES2324876T3 (es) Composiciones y metodos para el diagnostico de tumores.
WO2004075835A3 (fr) Procédés de traitement de carcinome
MXPA05004074A (es) Nuevos adenovirus, acidos nucleicos que los codifican y su uso.
ATE512159T1 (de) Cyclodipeptidsynthetasen und ihre verwendung zur synthese von cyclo(leu-leu)cyclodipeptid
WO2008067025A3 (fr) Adénovirus oncolytiques et utilisations de ceux-ci
WO2010006136A3 (fr) Ciblage d'adénovirus
WO2004071530A3 (fr) Compositions et methodes servant au diagnostic et au traitement de tumeurs
Wang et al. Targeting ANP32A is a novel strategy against leukemia

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: DOMPE' S.P.A. (IT)

Free format text: TRANSFERIDO POR FUSAO DE: DOMPE PHA.R.MA S.P.A.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2264 DE 27/05/2014.

B15K Others concerning applications: alteration of classification

Ipc: C07K 14/47 (2006.01), A61K 35/12 (2015.01)